This bill establishes a value-based payment system for West Virginia's Medicaid addiction care services, shifting from fee-for-service to rewarding providers based on patient recovery outcomes. It directly affects Medicaid providers treating substance use disorders by requiring them to use standardized billing codes starting in 2027 and report on five specific outcome metrics: housing stability, sobriety, avoidance of criminal justice involvement, self-sufficiency (employment/education), and provider transition plans. The bill mandates data collection and analysis by the Bureau for Medical Services to develop these metrics, with value-based payments requiring implementation by 2028. The goal is to create a coordinated care system focused on long-term recovery success rather than fragmented service volume.
SB 650 amends West Virginia law to define a psychiatric hospital treating exclusively civil and forensic patients (with over 95% of its inpatient census being court-ordered forensic or civil involuntary commitments from state custody) as a "state-designated facility" for tax purposes. This change excludes such hospitals from the category of "eligible acute care hospitals" subject to a 0.75% tax on gross receipts, exempting them from this tax. The bill directly affects psychiatric hospitals in West Virginia meeting this specific patient mix requirement by altering their tax classification under the Medicaid funding structure.
West Virginia Senate Bill 645 prohibits non-network ambulance services from charging patients extra fees beyond standard insurance cost-sharing. It requires insurers to pay non-participating ambulance providers directly at 400% of the Medicare rate (or the provider’s billed amount, whichever is lower) within 30 days of a clean claim. Patients cannot be billed for amounts beyond their standard copayments, coinsurance, or deductibles, and insurers must provide written denial notices with specific reasons. This applies to ground ambulance services covered under health insurance policies issued on or after January 1, 2027.
This bill (SB 570) allocates $199,476,099 in unspent federal funds to the West Virginia Department of Health's "Rural Health Transformation Program" for fiscal year 2026. It adds a new funding line (Fund 8802, Org 0506) under the Department's Central Office to support this specific program. The funds are designated for rural health initiatives and directly affect the Department of Health's ability to implement these programs. This is a procedural funding measure, not a policy change, using existing federal funds without new tax implications.
HB 4626 establishes a West Virginia grant program to fund U.S. Food and Drug Administration (FDA) drug development trials using ibogaine, a substance being studied for treating opioid use disorder and other neurological/mental health conditions. The program requires applicants (e.g., pharmaceutical companies or research organizations) to demonstrate capacity to conduct FDA trials, secure approval for ibogaine as a medication, and commit to establishing a state presence, securing insurance coverage, and ensuring treatment access for uninsured patients. Applicants must submit detailed trial designs, safety protocols, and plans for intellectual property rights and post-approval implementation, with grants administered through a state selection committee. The bill does not approve ibogaine but aims to accelerate its development pathway through state-funded trials.
SB 773 would require the West Virginia Department of Health to propose rules adding alpha-gal syndrome to the list of diseases that must be reported to the Centers for Disease Control and Prevention (CDC). Alpha-gal syndrome causes allergic reactions to red meat and is often triggered by tick bites. If enacted, healthcare providers in West Virginia would be required to report confirmed cases of this condition to the state health department, which would then share the data with the CDC. This change would improve public health tracking of alpha-gal syndrome cases in the state.
SB 805 adds "abortion pill reversal" to West Virginia's Mothers and Babies Pregnancy Support Program, allowing funding for this service through eligible pregnancy help organizations. The bill defines "abortion pill reversal" as using progesterone to counteract the abortion pill (mifepristone) and specifies that only organizations that do not support or perform abortions can receive program funds for this purpose. Abortion industry organizations are explicitly excluded from receiving these funds. This is a procedural change to the existing program's funding eligibility, not a new law restricting abortion access.
SB 1036 modernizes foster care funding in West Virginia by requiring the Department of Human Services to update basic, special, and therapeutic foster care payment rates using current cost data. It mandates automatic annual adjustments based on the Employment Cost Index (ECI) for Health Care & Social Assistance or the CPI-Medical index to keep pace with rising costs. The bill also requires therapeutic foster care and agency administrative rates to reflect current expenses and includes retention incentives for foster care providers. This directly affects foster parents, child-placing agencies, and the Department of Human Services by stabilizing workforce compensation and placement continuity. The changes aim to improve recruitment and retention in the child welfare system through updated, cost-based funding.
Senate Bill 956 removes requirements that physician assistants (PAs) in West Virginia must work under direct physician supervision or collaboration. It allows PAs to own medical businesses, practice independently without mandated supervision, and be held to the same standard of care as other licensed healthcare providers. The bill amends specific sections of West Virginia law (§30-3-14, §30-3-15, §31B-13-1301) and adds a new section (§30-3E-21) to formalize these changes, including classifying PAs as a "professional service" under business law. This directly affects PAs by expanding their scope of practice and business ownership opportunities.
SB 1012 amends West Virginia law to permit the development of 60 additional inpatient substance use disorder treatment beds specifically for youth aged 17 or younger in Cabell County. The bill modifies certificate of need requirements that previously restricted new beds in counties with over 250 existing substance abuse treatment beds, making an exception for Cabell County's juvenile beds. This policy change directly affects minors in Cabell County seeking inpatient treatment for substance use disorders by removing a regulatory barrier to expanding specialized care. The provision is limited to inpatient treatment beds exclusively for individuals 17 years or younger.
